Micro Abstract Hyperfractionated cyclophosphamide-dexamethasone (hyperCd) with or without carfilzomib and/or daratumumab is a potential treatment option for patients with multiple myeloma needing rapid disease control. This retrospective analysis of 97 patients describes the safety and efficacy of these regimens. With hyperCd-based therapy, rapid disease control is achievable. Associated hematologic toxicities occur frequently, but are manageable with aggressive supportive care.
All Keywords
【저자키워드】 Myeloma, Cyclophosphamide, Carfilzomib, daratumumab, plasma cell leukemia,
【저자키워드】 Myeloma, Cyclophosphamide, Carfilzomib, daratumumab, plasma cell leukemia,